Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Acupuncture

Deep Dive

From a western clinical standpoint, chemotherapy-induced peripheral neuropathy arises when neurotoxic agents injure peripheral sensory axons and... From a western clinical standpoint, chemotherapy-induced peripheral neuropathy arises when neurotoxic agents injure peripheral sensory axons and dorsal root ganglia. Patients typically report burning pain, tingling, numbness, cold sensitivity, and impaired balance or dexterity. Meta-analytic data indicate a high incidence during treatment and a meaningful proportion with persistent symptoms months to years later. In this context, the appeal of acupuncture is twofold: a favorable safety profile and plausible biological mechanisms for neuromodulation. Experimental studies show acupuncture can trigger endogenous opioid release, enhance descending inhibitory control (serotonergic and noradrenergic), modulate spinal cord and cortical pain processing, and reduce neuroinflammatory mediators—mechanisms that map onto known drivers of neuropathic pain and dysesthesia. Locally, needling can increase microcirculation and influence neurotrophic signaling, potentially relevant to numbness and cold sensitivity. Clinically, the evidence base for acupuncture in CIPN includes small randomized and pilot trials and observational cohorts. Several studies report improvements in patient-reported outcomes (e.g., FACT/GOG-Ntx, EORTC QLQ-CIPN20) and numeric pain ratings, with electroacupuncture sometimes demonstrating stronger effects. However, results are not uniformly positive, and the literature is limited by small samples, heterogeneity of acupuncture protocols and chemotherapy exposures, short follow-up, and the inherent difficulty of blinding with credible sham controls. Systematic reviews synthesize these data as suggestive of benefit but emphasize low to moderate certainty. Current guidelines endorse duloxetine for painful CIPN and recognize acupuncture as a reasonable adjunct when delivered by credentialed practitioners and coordinated with oncology care. Safety considerations for oncology patients are specific. With neutropenia or immunosuppression, meticulous sterile technique is mandatory; with thrombocytopenia or anticoagulation, shallow needling and pressure hemostasis may be necessary, and treatment may be deferred at very low platelet counts. Avoid needling through compromised skin (e.g., radiation dermatitis, active infection) and near central lines or tissue at risk for lymphedema. When used thoughtfully, reported adverse events are uncommon and mild. Overall, acupuncture can be considered as part of a multimodal CIPN strategy that also includes pharmacologic options, physical and occupational therapy, balance training, and exercise. Patients benefit from clear expectations about the uncertain but promising evidence and the need for ongoing evaluation of symptom change.